TY - JOUR
T1 - Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer
AU - Ovarian Tumor Tissue Analysis (OTTA) Consortium
AU - Goode, Ellen L.
AU - Block, Matthew S.
AU - Kalli, Kimberly R.
AU - Vierkant, Robert A.
AU - Chen, Wenqian
AU - Fogarty, Zachary C.
AU - Gentry-Maharaj, Aleksandra
AU - Tołoczko, Aleksandra
AU - Hein, Alexander
AU - Bouligny, Aliecia L.
AU - Jensen, Allan
AU - Osorio, Ana
AU - Hartkopf, Andreas D.
AU - Ryan, Andy
AU - Chudecka-Głaz, Anita
AU - Magliocco, Anthony M.
AU - Hartmann, Arndt
AU - Jung, Audrey Y.
AU - Gao, Bo
AU - Hernandez, Brenda Y.
AU - Fridley, Brooke L.
AU - McCauley, Bryan M.
AU - Kennedy, Catherine J.
AU - Wang, Chen
AU - Karpinskyj, Chloe
AU - de Sousa, Christiani B.
AU - Tiezzi, Daniel G.
AU - Wachter, David L.
AU - Herpel, Esther
AU - Taran, Florin Andrei
AU - Modugno, Francesmary
AU - Nelson, Gregg
AU - Lubiński, Jan
AU - Menkiszak, Janusz
AU - Alsop, Jennifer
AU - Lester, Jenny
AU - Garcia-Donas, Jesus
AU - Nation, Jill
AU - Hung, Jillian
AU - Palacios, Jose
AU - Rothstein, Joseph H.
AU - Kelley, Joseph L.
AU - de Andrade, Jurandyr M.
AU - Robles-Diaz, Luis
AU - Intermaggio, Maria P.
AU - Widschwendter, Martin
AU - Beckmann, Matthias W.
AU - Ruebner, Matthias
AU - Jimenez-Linan, Mercedes
AU - Sieh, Weiva
N1 - Funding Information:
Funding was provided by Canadian Institutes for Health Research (MOP-86727); Brazilian National Council for Scientific and Technological Development, grant No. 478416/ 2009-1; Calgary Laboratory Services Internal Research Competition RS10-533; German Federal Ministry of Education and Research of Germany (01 GB 9401); German Cancer Research Center (DKFZ); US National Cancer Institute K07-CA80668, P50-CA159981, R01CA095023; National Institutes of Health/National Center for Research Resources/ General Clinical Research Center grant MO1-RR000056; US Army Medical Research and Materiel Command DAMD17-02-1-0669; NIH (R01-CA122443, P50-CA136393, P30-CA15083, U01-CA71966, U01-CA69417, R01-CA16056, K07-CA143047); Cancer Research UK (C490/A10119, C490/A10123, C490/A16561); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge and at University College Hospital, ?Women?s Health Theme?; NIH SFB 685; the Eve Appeal; the Oak Foundation; and Deutsche Forschungsgemein-schaft. The Australian Ovarian Cancer Study Group was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729; The Cancer Council Victoria; Queensland Cancer Fund; The Cancer Council, New South Wales,; the Tom Baker Cancer Centre Translational Laboratories; The Cancer Council, South Australia; The Cancer Foundation of Western Australia; The Cancer Council Tasmania; and the National Health and Medical Research Council of Australia (NHMRC; ID400413, ID400281). The AOCS gratefully acknowledges additional support from the Peter MacCallum Cancer Foundation and Ovarian Cancer Australia (OCA). The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was funded by the National Health and Medical Research Council Enabling grants ID 310670 and ID 628903 and the Cancer Institute NSW grants 12/RIG/1-17 and 15/RIG/1-16. Funding for MALOVA was provided by research grant R01-CA61107 from the National Cancer Institute, Bethesda, Maryland; research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project. Drs DeFazio and Harnett are funded by Cancer Institute NSW grant 15/TRC/1-01. Dr Karlan is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000124.
Publisher Copyright:
© 2017 American Medical Association. All rights reserved.
PY - 2017/12
Y1 - 2017/12
N2 - IMPORTANCE Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. OBJECTIVE To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. EXPOSURES Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. MAIN OUTCOMES AND MEASURES Overall survival time. RESULTS The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. CONCLUSIONS AND RELEVANCE This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
AB - IMPORTANCE Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. OBJECTIVE To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. EXPOSURES Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. MAIN OUTCOMES AND MEASURES Overall survival time. RESULTS The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. CONCLUSIONS AND RELEVANCE This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
UR - http://www.scopus.com/inward/record.url?scp=85044128994&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2017.3290
DO - 10.1001/jamaoncol.2017.3290
M3 - Article
C2 - 29049607
AN - SCOPUS:85044128994
SN - 2374-2437
VL - 3
JO - JAMA Oncology
JF - JAMA Oncology
IS - 12
M1 - e173290
ER -